StageZero Life Sciences Ltd
TSX:SZLS
StageZero Life Sciences Ltd
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. The company is headquartered in Richmond Hill, Ontario and currently employs 80 full-time employees. The firm has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. The firm offers ColonSentry product, which is a blood test to determine an individual’s current risk for having colorectal cancer. The company offers Aristotle, a mRNA-based multi-cancer detection panel for simultaneously screening of various cancers from a single sample of blood. In addition, the Company offers various COVID-19 tests, including polymerase chain reaction (PCR) tests and antibody tests. Its PCR tests can detect COVID-19 nucleic acid from patient nasopharyngeal swab specimens or saliva and are used to diagnose an active COVID-19 infection.
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. The company is headquartered in Richmond Hill, Ontario and currently employs 80 full-time employees. The firm has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. The firm offers ColonSentry product, which is a blood test to determine an individual’s current risk for having colorectal cancer. The company offers Aristotle, a mRNA-based multi-cancer detection panel for simultaneously screening of various cancers from a single sample of blood. In addition, the Company offers various COVID-19 tests, including polymerase chain reaction (PCR) tests and antibody tests. Its PCR tests can detect COVID-19 nucleic acid from patient nasopharyngeal swab specimens or saliva and are used to diagnose an active COVID-19 infection.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
